Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Singer, E ^a   Judkins, J ^a   Salomonis, N ^b   Matlaf, L ^a   Soteropoulos, P ^c   McAllister, S ^a   Soroceanu, L ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CASPASE 3; GLUTATHIONE; INHIBITOR OF DIFFERENTIATION 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; KI 67 ANTIGEN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PIPERAZINE DERIVATIVE; PIPERAZINE ERASTINE; PLATELET DERIVED GROWTH FACTOR A; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTIOXIDANT; ERASTIN; SLC7A11 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL FRACTIONATION; CELL INVASION; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; FEMALE; GENE SILENCING; GLIOBLASTOMA; HUMAN; IC50; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MODEL; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MESODERM; METABOLISM; NERVE CELL; NUDE MOUSE; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

MUS;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CANNABIDIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; MESODERM; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; NEURONS; NF-E2-RELATED FACTOR 2; PHENOTYPE; PIPERAZINES; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925593582     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.566     Document Type: Article

References (34)

1. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
2. TCGA C. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
4. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2012; 123: 517-525.
5. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013; 24: 331-346.
6. Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013; 110: 8644-8649.
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
8. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3: 420-425.
9. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009; 11: 3013-3069.
10. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956.
11. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2012; 75: 303-312.
12. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12: 436-444.
13. Akhavan A, Griffith OL, Soroceanu L, Leonoudakis D, Luciani-Torres MG, Daemen A et al. Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res 2012; 72: 2578-2588.
14. Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 2013; 73: 1559-1569.
15. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
16. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012; 16: 1215-1228.
17. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
18. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 2012; 32: 687-726.
19. Lyons SA, Chung WJ,Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67: 9463-9471.
20. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-1072.
21. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014; 3: e02523.
22. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156: 317-331.
23. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 2004; 308: 838-845.
24. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008; 104: 1091-1100.
25. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 2012; 168: 79-102.
26. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiolinduced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006; 70: 897-908.
27. Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol 2014; 171: 4464-4477.
28. Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 2012; 26: 1535-1548.
29. Sato A, Okada M, Shibuya K, Watanabe E, Seino S, Narita Y et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of gliomainitiating cells. Stem Cell Res 2014; 12: 119-131.
30. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
31. Savaskan NE, Eyupoglu IY. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Ann Anat 2010; 192: 309-313.
32. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
33. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013; 24: 450-465.
34. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2013; 10: 9-17.